Results 61 to 70 of about 28,652 (194)

Efficacy of rivaroxaban for pulmonary embolism

Medicine, 2019
Abstract Background: Previous clinical trials have addressed that rivaroxaban is effective for the treatment of patients with pulmonary embolism (PE). This study will systematically assess its efficacy and safety for PE. Methods: We will carry out this study by searching
Ning Xu, Shi-min Xue, Juan Jia
openaire   +3 more sources

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

PLoS ONE
BackgroundThe European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice ...
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez   +9 more
doaj   +1 more source

Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery

Orthopaedic Surgery, 2019
Objective To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS).
Qiang Huang, Shu‐xing Xing, Yi Zeng, Hai‐bo Si, Zong‐ke Zhou, Bin Shen   +5 more
doaj   +1 more source

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement [PDF]

, 2006
Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Eva Muehlhofer, Christoph Dierig, Frank Misselwitz, Peter Kälebo   +9 more
openalex   +1 more source

A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting

BMC Health Services Research, 2012
Background Patients undergoing major orthopaedic surgery (MOS), such as total hip (THR) or total knee replacement (TKR), are at high risk of developing venous thromboembolism (VTE).
Zindel Sonja, Stock Stephanie, Müller Dirk, Stollenwerk Björn   +3 more
doaj   +1 more source

Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen [PDF]

, 2006
Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf   +3 more
openalex   +1 more source

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban [PDF]

, 2007
Grigoris Gerotziafas, Ismaı̈l Elalamy, François Depasse, Elisabeth Perzborn, M Samama   +4 more
openalex   +1 more source

Rapid Determination of Rivaroxaban by Using Terahertz Metamaterial Biosensor

Photonics
Rivaroxaban, a direct oral anticoagulant, is widely used in the management and prevention of thrombotic conditions. Dose adjustments are necessary to optimize efficacy based on individual physiological differences. However, current analytical methods are
Xinghao Huang, Jing Wu, Xu Wu, Yan Peng
doaj   +1 more source

Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation

CJC Open, 2021
Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation
Jiaming (Calvin) Liang, MD, MSc, Karanvir Raman, BBA, Siu Him Chan, MD, A. Yashar Tashakkor, MD   +3 more
doaj  

Treatment of Proximal Deep-Vein Thrombosis with the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) Study [PDF]

, 2008
G. Agnelli, A. Gallus, S.Z. Goldhaber
openalex   +1 more source